Showing 2921-2930 of 3315 results for "".
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- FDA Approves Bausch + Lomb Alaway Preservative Free OTC Dropshttps://modernod.com/news/fda-approves-bausch-lomb-alaway-preservative-free-ophthalmic-solution/2478329/Bausch + Lomb and Eton Pharmaceuticals announced that the FDA has approved Alaway Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy
- US Eye Network Expands into Southeastern US through Partnership with Carolina Eyecare Physicianshttps://modernod.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/Carolina Eyecare Physicians has joined the expanding US Eye network. With the addition of Carolina Eyecare Physicians, US Eye, a physician-led network of practices, will operate 24 clinics and 3 surgery centers. <
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edemahttps://modernod.com/news/emmecell-announces-fda-acceptance-of-ind-application-for-eo2002-in-corneal-edema/2478310/Emmetrope Ophthalmics announced that the FDA has accepted the investigational new drug application (IND) for EO2002, its lead candidate for the treatment of corneal edema. The active IND enables Emmecell to initiate a phase 1 clinical trial designed to assess the tolerability, safety, and efficac
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Ophthalmic Societies Call on FDA to Keep Moxifloxacin on Bulk Substance Listhttps://modernod.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/Several ophthalmic organizations have collectively sent a letter to the FDA requesting that the agency retain moxifloxacin as Category 1 for outsourcing facility use (503b), citing a demonstrated clinical need for the medication as a bulk substance. The request comes after the FDA, on July 31, ga
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V